Previous Close | 16.4 |
1-Year Change | -14.72% |
6-Months Change | 5.87% |
3-Months Change | -19.37% |
Moving Avg (50d) | 18.94 |
Moving Avg (200d) | 17.734 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.717B |
Beta (3-Years) | 0.92 |
Revenue Growth (ttm) | -81.55% |
Net Profit Margin (ttm) | -62437.75% |
Return On Assets (ttm) | -65.9% |
EPS (ttm) | -5.14 |
PE Ratio (ttm) | -3.19 |
Dividend Yield | % |
Asset Description: | Viridian Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
16.072 | 15.58 | 15.252 | 14.76 | 13.94 | 13.12 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |